- Advanced search
- Immuno Portal
- Malaria Portal
|IL-17A and IL-17F are important cytokines in the host response against many extracellular pathogens, but are also recognised to cause excessive tissue damage and exacerbate proinflammatory responses during autoimmunity. A molecular mechanism underlying IL-17's role in the disease process of RA is proposed by Ganesan and Rasool (2017) . The IL-17 pathway is therefore a major therapeutic target in autoimmune diseases.
A study that investigated the potential of using mesenchymal stromal cells (MSCs) as prophylactic and therapeutic agents against the acute rejection of lung grafts (in rats) identified MSC-induced down-regulation of IL-17A by allografts as a major contributor to reduced markers of inflammation and graft rejection . In addition, MSC treatment promoted expression of PD-L1 on the grafts, which implicates a PD-1/PD-L1 driven inhibition of immune responses in the protective effects of MSC therapy.
|Approved therapy for MS.|
||Approved therapy for psoriasis.|
|Approved therapy for RA.|
||Approved therapy for PsA.|
||Approved therapy for systemic ankylosing spondylitis.|